Experts Highlight FDA’s Push for Bespoke Genetic Therapy Pathway

Health experts say a new FDA policy framework could mark a turning point for highly individualized genetic medicines, as regulators attempt to keep pace with technologies that can now design treatments for single patients. In a commentary published in JAMA Health Forum, former FDA commissioner Scott Gottlieb and regulatory expert Maarika Kimbrell argue the agency’s draft guidance on individualized therapies is a “promising” step toward enabling so-called N-of-1 treatments — bespoke drugs tailored to a patient’s specific genetic mutation.

The shift reflects a broader inflection point in medicine. Since FDA’s first gene therapy approval in 2017, the field has expanded to include dozens of gene and cell therapies, along with RNA-based drugs that can silence disease-causing genes. Increasingly, those tools are being used not just to treat diseases, but to target unique genetic variants in individual patients.

FDA’s draft framework attempts to address that reality by allowing developers to anchor approval around a core therapeutic platform — such as a viral vector or oligonucleotide backbone — and then modify components of the therapy to match specific mutations without starting the regulatory process from scratch each time.

That concept, if fully realized, could dramatically compress development timelines for rare genetic diseases, where traditional drug development models are often impractical due to tiny patient populations.

Gottlieb and Kimbrell note that key questions remain unresolved.

Among them:

• How broadly regulators will allow data extrapolation across different genetic variants
• What defines the boundary of a “platform” therapy versus a new product
• How manufacturing standards will be applied when each batch may be made for a single patient
• What role postmarket data and registries will play in building evidence over time

The authors argue that greater clarity in these areas will be critical to making the pathway usable for developers, particularly around how much clinical evidence is required when datasets may include only a handful of patients. They also point to manufacturing as a potential bottleneck, especially as some personalized therapies may need to be produced at or near the point of care rather than in centralized facilities.

For now, FDA’s guidance remains in draft form, with further refinement expected later this year. But the direction is clear: regulators are signaling a willingness to rethink traditional approval paradigms in order to accommodate a new generation of therapies that blur the line between drug development and individualized care.

The challenge, as the authors frame it, will be balancing that flexibility with the agency’s longstanding evidentiary standards — particularly in a space where clinical data may be limited, but the stakes for patients are exceptionally high.